РАСПРОСТРАНЕННЫЕ ОШИБКИ В АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ


Цитировать

Полный текст

Аннотация

Обсуждаются наиболее распространенные ошибки при проведении антигипертензивной терапии и подходы к их устранению

Об авторах

В В Фомин

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

В В Панасюк

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

Список литературы

  1. Kostis W.J., Thijs L., Richart T. et al. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications. Hypertension. 2010 Oct 25. [Epub ahead of print]
  2. Bramlage P., Böhm M., Volpe M. et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J. Clin. Hypertens. (Greenwich). 2010; 12(9): 666-677
  3. Frohlich E.D. The necessity for recognition and treatment of patients with "mild" hypertension. J. Am. Coll. Cardiol. 1999; 34: 1369 - 1377
  4. Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988 - 2000. J.A.M.A. 2003; 290: 199 - 206
  5. Macedo M.E., Lima M.J., Silva A.O. et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J. Hypertens. 2005; 23: 1661 - 1666
  6. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертензия: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал. 2006; 4: 45-50
  7. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Качество профилактики и лечения сердечно-сосудистых заболеваний и их осложнений у больных сахарным диабетом 2 типа в амбулаторных условиях. Кардиоваскулярная терапия и профилактика 2008; 7(7): 9 - 14
  8. Чазов Е.И. Пути снижения смертности от сердечно-сосудистых заболеваний. Тер. арх. 2008; 80(8): 11-16
  9. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010; 3: 5-26
  10. McKay D.W., Campbell N.R., Parab L.S. et al. Clinical assessment of blood pressure. J. Hum Hypertens. 1990; 4: 639-645
  11. Isaacs A.J., Critchley J.A., Tai S.S. et al. Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only. Health Technol. Assess. 2007; 11(10): 1-165
  12. Farpour-Lambert N.J., Aggoun Y., Marchand L.M. et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J. Am. Coll. Cardiol. 2009; 54(25): 2396-2406
  13. Sugawara J., Otsuki T., Tanabe T. et al. Physical activity duration, intensity, and arterial stiffening in postmenopausal women. Am. J. Hypertens. 2006; 19(10): 1032-1036
  14. Gando Y., Yamamoto K., Murakami H. et al. Longer time spent in light physical activity is associated with reduced arterial stiffness in older adults. Hypertension. 2010; 56(3): 540-546
  15. Law M. Salt, blood pressure and cardiovascular diseases. J. Cardiovasc. Risk. 2000; 7: 5 - 8
  16. Destro M., Crikelair N., Yen J., Glazer R. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc. Health Risk Manag. 2010; 6: 821-827
  17. Okin P.M., Hille D.A., Kjeldsen S.E. et al. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. Am. J. Hypertens. 2010; 23(7): 786-793
  18. Lindholm L.H., Carlberg B., Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545 - 1553
  19. Dahlof B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895 - 906
  20. Zillich A.J., Garg J., Basu S. et al. Thiazide diuretics, potassium and the development of diabetes. A quantative review. Hypertension 2006; 48: 219 - 224
  21. Marazzi G., Volterrani M., Caminiti G. et al. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv. Ther. 2010; 27(9): 655-664
  22. Dragomir A., Côté R., Roy L. et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med. Care. 2010; 48(5): 418-425
  23. Bramley T.J., Gerbino P.P., Nightengale B.S., Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J. Manag. Care Pharm. 2006; 12(3): 239-245
  24. Fodor G.J., Kotrec M., Bacskai K. et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J. Hypertens. 2005; 23: 1261 - 1266
  25. Roth A., Kalter-Leibovici O., Kerbis Y. et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin. Cardiol. 2003; 26: 25 - 30
  26. Aranda P., Ruilope L.M., Calvo C. et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am. J. Hypertens. 2004; 17: 139 - 145
  27. Wannemacher A.J., Schepers G.P., Townsend K.A. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann. Pharmacother. 2002; 36: 986 - 991
  28. Salas M., In't Veld B.A., van der Linden P.D. et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin. Pharmacol. Ther. 2001; 70: 561 - 566
  29. Chapman R.H., Benner J.S., Petrilla A.A. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 165: 1147 - 1152
  30. Schroeder K., Fahey T., Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst. Rev. 2004; 2: CD004804
  31. Neutel J.M., Saunders E., Bakris G.L. et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J. Clin. Hypertens. (Greenwich). 2005; 7(10): 578-586
  32. Chrysant S.G., Neutel J.M., Ferdinand K.C.; INCLUSIVE investigators. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J. Natl. Med. Assoc. 2009; 101(4): 300-307
  33. Schmieder R.E., Schwertfeger M., Bramlage P. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vasc. Health Risk Manag. 2009; 5: 991-1000
  34. Franklin S.S., Neutel J.M. Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. J. Clin. Hypertens. (Greenwich). 2010; 12(7): 487-494

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах